BR112018072197A2 - amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal - Google Patents

amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal

Info

Publication number
BR112018072197A2
BR112018072197A2 BR112018072197A BR112018072197A BR112018072197A2 BR 112018072197 A2 BR112018072197 A2 BR 112018072197A2 BR 112018072197 A BR112018072197 A BR 112018072197A BR 112018072197 A BR112018072197 A BR 112018072197A BR 112018072197 A2 BR112018072197 A2 BR 112018072197A2
Authority
BR
Brazil
Prior art keywords
moma
real time
time pcr
multiple optimized
fetal well
Prior art date
Application number
BR112018072197A
Other languages
English (en)
Portuguese (pt)
Inventor
Tomita Mitchell Aoy
Stamm Karl
Original Assignee
Medical College Wisconsin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College Wisconsin Inc filed Critical Medical College Wisconsin Inc
Publication of BR112018072197A2 publication Critical patent/BR112018072197A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112018072197A 2016-04-29 2017-04-29 amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal BR112018072197A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330044P 2016-04-29 2016-04-29
PCT/US2017/030292 WO2017190105A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing fetal well being

Publications (1)

Publication Number Publication Date
BR112018072197A2 true BR112018072197A2 (pt) 2019-02-12

Family

ID=60161136

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072197A BR112018072197A2 (pt) 2016-04-29 2017-04-29 amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal

Country Status (11)

Country Link
US (1) US20190153525A1 (https=)
EP (1) EP3449018A4 (https=)
JP (1) JP2019514387A (https=)
CN (1) CN109661476A (https=)
AU (1) AU2017258800A1 (https=)
BR (1) BR112018072197A2 (https=)
CA (1) CA3022548A1 (https=)
EA (1) EA201892490A1 (https=)
IL (1) IL262641A (https=)
MX (1) MX2018013261A (https=)
WO (1) WO2017190105A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
WO2018085597A1 (en) * 2016-11-02 2018-05-11 Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
JP2019534016A (ja) * 2016-11-02 2019-11-28 ザ メディカル カレッジ オブ ウィスコンシン,インコーポレイテッドThe Medical College of Wisconsin, Inc. 全および特異的な無細胞dnaを使用しリスクを評価するための方法
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599608A4 (en) * 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
EP2351858B1 (en) * 2006-02-28 2014-12-31 University of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
PL2791325T3 (pl) * 2011-12-16 2018-08-31 Basf Agrochemical Products, B.V. Sposoby i kompozycje do analizy genów ahasl w pszenicy
WO2014143989A1 (en) * 2013-03-15 2014-09-18 Medical College Of Wisconsin, Inc. Fetal well being surveillance using fetal specific cell free dna
WO2015178978A2 (en) * 2014-02-14 2015-11-26 The Board Of Regents Of The University Of Texas System Strand exchange hairpin primers that give high allelic discrimination
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Also Published As

Publication number Publication date
JP2019514387A (ja) 2019-06-06
IL262641A (en) 2018-12-31
US20190153525A1 (en) 2019-05-23
AU2017258800A1 (en) 2018-12-20
EP3449018A4 (en) 2019-11-06
CN109661476A (zh) 2019-04-19
EP3449018A1 (en) 2019-03-06
CA3022548A1 (en) 2017-11-02
MX2018013261A (es) 2019-04-22
WO2017190105A1 (en) 2017-11-02
EA201892490A1 (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
BR112018072197A2 (pt) amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal
BR112018072195A2 (pt) amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer
BR112018072196A2 (pt) amplificação de incompatibilidade otimizada multiplexadas (moma) - número do alvo
BR112017023232A2 (pt) pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células
BR112017008082A2 (pt) composições e métodos para detectar um vírus de rna
BR112018074979A2 (pt) composições de limpeza que compreendem enzimas
MX2019005199A (es) Métodos para evaluar el riesgo usando and libre de células total y específico.
BR112015032031A8 (pt) método para estimar uma fração de ácido nucleico em uma amostra de teste de uma mulher grávida
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112016019940A2 (pt) edição de genoma sem nucleases
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
IN2014DN08831A (https=)
Zhao et al. Association between the ACE I/D polymorphism and risk of ischemic stroke: An updated meta-analysis of 47,026 subjects from 105 case–control studies
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
WO2015195949A3 (en) Methods, compositions, and devices for rapid analysis of biological markers
MX2018002955A (es) Acido nucleico antisentido.
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
MX386087B (es) Composiciones y metodos para mejorar y/o predecir la amplificacion de adn.
MX390053B (es) Metodos de evaluacion genomica en ganado.
WO2015185672A3 (en) New markers for the assessment of an increased risk for mortality
MX366113B (es) Metodos de diganostico y composiciones.
BR112016025971A2 (pt) ?grelhador?
BR112017007733A2 (pt) método para quantificação de um ácido nucleico alvo, e, kit.
WO2019103421A3 (ko) 유전자의 cpg 메틸화 변화를 이용한 간암의 예후 또는 위험도를 평가하는 방법

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.